Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lynparza in pediatric tumors with DNA damage repair defects
NCT03233204Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of olaparib in solid tumor, non-Hodgkin lymphoma (NHL), histiocytic disorder, sponsored by National Cancer Institute. Started Sep 2017; status: completed.
02
Drugs
olaparib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorder
Beyond the preview
Go deeper on NCT03233204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233204.